Developing a blood test for early detection of breast cancer, pancreatic cancer, and multiple myeloma
Official title: Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma
Funded at University of Southern California · NIH-10930880 · Data updated 2026-11-12
This study is working on a new blood test that can help find early signs of breast cancer, pancreatic cancer, and multiple myeloma, so patients can get diagnosed sooner and have better treatment options.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $662,340 |
| NIH project number | 5U01CA285013-02 |
| Project ID | NIH-10930880 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk for or suspected of having breast cancer, pancreatic cancer, or multiple myeloma.
✕Less likely to help
Patients with cancers not included in this research or those who are not at risk for the specified cancers may not benefit from this research.
What this research studies
This research focuses on creating and validating a multi-analyte liquid biopsy technology that can detect early signs of breast cancer, pancreatic cancer, and multiple myeloma through blood samples. By analyzing various biomarkers released by tumors into the bloodstream, the study aims to improve early cancer assessment and diagnosis. The research will involve collaboration among clinical, research, and industry experts to ensure the technology is effective and ready for clinical use. Patients may benefit from more accurate and earlier detection of these cancers, potentially leading to better treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of breast cancer, pancreatic cancer, and multiple myeloma, improving patient outcomes.
How similar studies have gone: Other research has shown promise in using liquid biopsy technologies for cancer detection, indicating that this approach has potential for success.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Kuhn, Peter — University of Southern California
- Study coordinator: Kuhn, Peter
Related research
Other NIH-funded projects on the same topics.
-
Multi-analyte blood and fluid tests to find breast, pancreatic cancer, and multiple myeloma earlier
Researchers are creating combined blood and body-fluid tests to help find breast cancer, pancreatic cancer, and multiple myeloma earlier for people having screening or diagnostic workups.
-
Blood-based DNA markers plus imaging to track multiple myeloma
This project uses a blood test that reads DNA epigenetic marks together with PET/CT scans to better track disease in adults with multiple myeloma.
-
Using blood tests and imaging to track treatment response in multiple myeloma
This study is looking at how blood tests and imaging scans can work together to help doctors better understand how well treatments are working for people with multiple myeloma, making it easier and less invasive than traditional methods.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.